Gill Dines
Directeur des opérations chez UCB Pharma Ltd.
Profil
Gill Dines is a professional with experience in various firms.
Currently, Ms. Dines is the Head of Operations at UCB Pharma Ltd.
Ms. Dines has previously worked as the Director of Preclinical Development at RespiVert Ltd., Director & Head of Inhalational Toxicology at Glaxo Wellcome UK Ltd., and as a Principal at GSK Plc.
Ms. Dines has an undergraduate degree from the University of Leeds and a graduate degree from the University of Surrey.
Postes actifs de Gill Dines
| Sociétés | Poste | Début |
|---|---|---|
UCB Pharma Ltd.
 UCB Pharma Ltd. Pharmaceuticals: MajorHealth Technology UCB Pharma Ltd. operates as a biopharmaceutical company. The firm focuses on developing medicines for severe diseases in Immunology and CNS. The company is headquartered in Slough, the United Kingdom. | Directeur des opérations | 01/03/2018 |
Anciens postes connus de Gill Dines
| Sociétés | Poste | Fin |
|---|---|---|
| GSK PLC | Corporate Officer/Principal | - |
Glaxo Wellcome UK Ltd.
 Glaxo Wellcome UK Ltd. Financial ConglomeratesFinance Part of GSK Plc, Glaxo Wellcome UK Ltd. is a biopharma company that unites science, technology, and talent to get ahead of disease together. The company is based in Brentford, UK. The British company explore innovations from inside and outside their labs and are constantly looking for the world's best talent to help them discover and develop new products. #behindthescience, they have a purpose to unite science, technology, and talent to get ahead of disease together. Founded in 1950, the company's portfolio spans three product areas: vaccines, specialty, and general medicines. | Directeur/Membre du Conseil | - |
RespiVert Ltd.
 RespiVert Ltd. Medical DistributorsDistribution Services RespiVert Ltd. operates as a small molecule drug discovery company. The firm develops small-molecule inhaled therapies for the treatment of chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. The company was founded by William Garth Rapeport, Peter Strong, Kazuhiro Ito, John Murray and Peter Barnes in 2007 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
Formation de Gill Dines
| University of Leeds | Undergraduate Degree |
| University of Surrey | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GSK PLC | Health Technology |
| Entreprise privées | 3 |
|---|---|
RespiVert Ltd.
RespiVert Ltd. Medical DistributorsDistribution Services RespiVert Ltd. operates as a small molecule drug discovery company. The firm develops small-molecule inhaled therapies for the treatment of chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. The company was founded by William Garth Rapeport, Peter Strong, Kazuhiro Ito, John Murray and Peter Barnes in 2007 and is headquartered in London, the United Kingdom. | Distribution Services |
Glaxo Wellcome UK Ltd.
Glaxo Wellcome UK Ltd. Financial ConglomeratesFinance Part of GSK Plc, Glaxo Wellcome UK Ltd. is a biopharma company that unites science, technology, and talent to get ahead of disease together. The company is based in Brentford, UK. The British company explore innovations from inside and outside their labs and are constantly looking for the world's best talent to help them discover and develop new products. #behindthescience, they have a purpose to unite science, technology, and talent to get ahead of disease together. Founded in 1950, the company's portfolio spans three product areas: vaccines, specialty, and general medicines. | Finance |
UCB Pharma Ltd.
UCB Pharma Ltd. Pharmaceuticals: MajorHealth Technology UCB Pharma Ltd. operates as a biopharmaceutical company. The firm focuses on developing medicines for severe diseases in Immunology and CNS. The company is headquartered in Slough, the United Kingdom. | Health Technology |
